Nov. 7, 2025 — Coreline Soft will introduce its chest AI platform AVIEW 2.0 at RSNA 2025 (Nov. 30 – Dec. 4, Chicago), demonstrating how unified AI automation is fundamentally transforming radiology workflows and elevating diagnostic precision across pulmonary, cardiac, and airway pathologies.

Nov. 10, 2025 — Scientists at the University of Birmingham have developed a new class of MRI contrast agents – improving their stability to create a significant advancement in medical imaging technology.

Metallo coiled coils had offered exciting opportunities for use in MRI, but their advancement was limited by poor stability. Researchers have now overcome this challenge - making these synthetic protein-like structures viable candidates to develop for use with patients.

Nov. 4, 2025 — Virtual Radiologic (vRad) recently announced the successful commercialization of The vRad Platform — a fully integrated, AI-enabled technology and support platform for radiology practices. The vRad Platform optimizes radiologist productivity, provides practice-wide analytics in real time, and helps radiology practices deliver consistent, high-quality patient care across dispersed facilities and reading locations.

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI-Lung. 

The RevealDX product, RevealAI-Lung, characterizes nodules by producing a score called the Malignancy Similarity Index (mSI) to assist radiologists with the creation of follow-up recommendations. The company has validated the software on more than 1,500 patients from a variety of cohorts. RevealAI-Lung is the first device with claims for lung nodules that certifies it reduces time to diagnosis and reduces false positives. 

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara Health Technologies will now operate under the Lunit brand, introducing a unified global identity that merges their complementary strengths in breast health and AI innovation. This builds on Lunit’s 2024 acquisition of Volpara, an important step that aligned both companies under one vision: to conquer cancer through AI.

The Expansion of Teleradiology

Once viewed as a solution for after-hours coverage, teleradiology is rapidly expanding into a critical part of radiology department workflows.

“All radiologists are teleradiologists now,” says Morris Panner, president of Intelerad Medical Systems, a Montreal-based provider of medical imaging software platforms. “The notion that you will not use cloud or distributed technology to enable your practice and your ability to care for people — those days are gone.”

Nov. 4, 2025 — Altamont Software, a provider of enterprise medical connectivity solutions, has announced the availability of its Dynamic Content engine within Passport SR. This feature provides the ability to calculate numerical values or generate text from data received from modalities and insert it into a report template.

Oct. 28, 2025 — Using targeted radiation during surgery — referred to as intraoperative radiation — to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%. This is believed to be the lowest ever reported for this population of patients, according to a preliminary study by the team from the Johns Hopkins Kimmel Cancer Center.

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar titled “Quantitative Transmission Imaging Technology: The Future of Breast Imaging with Safe Volumetric Ultrasound” at the upcoming annual meeting of the Radiological Society of North America (RSNA 2025)  in Chicago, IL, Nov. 30 to Dec. 4, 2025.

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine. The regimen, which pre-treats the tumor before delivering targeted alpha-radioimmunotherapy, resulted in durable major responses — including histologic cures — with minimal toxicities, paving the way for a safer and more effective treatment option for breast cancer patients.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now